在第一线治疗期间，高级非小细胞肺癌患者的体重和身体成分的频率增加

这项研究的主要目的是评估身体成分的增加频率及其与两个现实世界中的两种治疗，晚期非小细胞肺癌（NSCLC）患者的体重变化的关系。一个队列获得了当前的护理标准（CSOC），该标准包括免疫疗法和新的化学疗法方案，另一个队列接受了以前的护理标准（FSOC）（FSOC），仅由较旧的铂型固有方案组成。CSOC.CSOC.CSOC（n = 106）和FSOC（N = 88）（n = 88）的COHORT（n = 88）的同类患者包括该研究。在每次临床访问中收集权重，并通过在基线和6周和12周时评估的自动分割软件进行常规胸部计算机断层扫描的身体组成分析。标准统计方法用于计算体重变化与人体组成之间的关系。CSOCCOHORT包含106阶段IV NSCLC患者，在16/12/2014和22/10/2020之间进行了治疗，而FSOC同事包含88阶段III/IV阶段NSCLC患者，在16/6/6/2006和18/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/11/114中进行了治疗。尽管每个队列的体重中值降低，但体重指数（BMI），平均骨骼肌指数（SMI）和皮下脂肪组织指数（SATI）在6周和12周的时间点，这些参数的一部分患者会增加。在12周的时间点，使用重量，BMI，SMI和SATI的阈值≥2.5％，两个同类群体的阈值在这些参数上均显示出相似的（20.5％和27.3％）。在12周随访中的切口点≥5％，其中8.0％至25.0％的体重，BMI，SMI和SATI的体重≥5％。在每个队列中比较这些结果没有显着差异。重量变化的皮尔逊系数与SMI和SATI的变化有关，在6和12周之间为0.31至0.58，所有P值<0.02。与Vati和Imati变化相关的12周重量变化的Pearson系数范围为0.26至0.47，所有P值<0.05。每个队列的皮尔逊系数的比较均未显示出显着差异。这些发现，加上体重，肌肉质量和脂肪组织的纵向测量之间的正相关，表明这些患者的体重增加涉及肌肉质量和脂肪组织的增加。经过验证，这些发现可能对临床试验设计和癌症恶病质研究具有影响。

The primary objective of this study was to assess the frequency of body composition increases and their relationships to changes in body weight in two cohorts of real world, treatment-naïve, advanced non-small cell lung cancer (NSCLC) patients. One cohort received the current standard of care (CSOC), which consisted of immunotherapy and newer chemotherapy regimens, and the other cohort was treated with the former standard of care (FSOC), consisting only of older platinum-containing regimens.CSOC (n = 106) and FSOC (n = 88) cohorts of advanced NSCLC patients were included in this study. Weights were collected at each clinical visit, and body composition analysis from routine chest computed tomography via automated segmentation software assessed at baseline and at 6 and 12 weeks. Standard statistical methods were used to calculate relationships between changes in weight and in body composition.The CSOC cohort contained 106 stage IV NSCLC patients treated between 16/12/2014 and 22/10/2020 while the FSOC cohort contained 88 stage III/IV NSCLC patients treated between 16/6/2006 and 18/11/2014. While each cohort exhibited decreases in median weight, body mass index (BMI), mean skeletal muscle index (SMI) and subcutaneous adipose tissue index (SATI) at the 6 and 12 week time points, a subset of patients experienced increases in these parameters. Using a threshold of ≥2.5% increase for weight, BMI, SMI, and SATI at the 12 week time point, both cohorts showed similar (20.5% and 27.3%) increases in these parameters. With a cut point of ≥5% increase at 12 weeks follow-up, 8.0% to 25.0% of the patients gained ≥5% in weight, BMI, SMI and SATI. Comparing these results in each cohort showed no significant differences. Pearson coefficients for weight change related to changes in SMI and SATI at 6 and 12 weeks ranged from 0.31 to 0.58 with all P values <0.02. Pearson coefficients for weight change at 12 weeks related to changes in VATI and IMATI ranged from 0.26 to 0.47 with all P values <0.05. Comparison of Pearson coefficients for each cohort showed no significant differences.Although decreases in median weight, BMI, SMI and SATI were observed in both cohorts, similar percentage of patients in each cohort experienced increases in these parameters. These findings, plus the positive correlations between longitudinal measurements of weight, muscle mass and adipose tissue, indicate that weight gain in these patients involves increases in both muscle mass and adipose tissue. Upon validation, these findings could have implications for clinical trial design and for translational research in cancer cachexia.